share_log

賽生藥業：根據收購守則規則3.8刊發的公告

SCICLONE PHARMA: ANNOUNCEMENT PURSUANT TO RULE 3.8 OF THE TAKEOVERS CODE

香港交易所 ·  Apr 3 08:57
Summary by Moomoo AI
賽生藥業控股有限公司於2024年4月3日宣布，其首次公開發售後購股權計劃項下授出的27,740份購股權已經被行使，從而發行了相同數量的新股份。此舉使得公司的已發行股份總數達到627,716,432股。此外，公司還披露了其餘未行使的購股權數量，包括購股權激勵計劃和首次公開發售後購股權計劃下授出的購股權，總計70,162,072份。公司提醒股東及潛在投資者，關於私有化的建議、計劃及購股權要約的實行仍需滿足特定條件或獲得豁免，並建議在買賣公司證券時應謹慎行事。董事會對公告內容的準確性承擔責任，並確認經過合理查詢後，公告中的資料無遺漏且無誤導性陳述。
賽生藥業控股有限公司於2024年4月3日宣布，其首次公開發售後購股權計劃項下授出的27,740份購股權已經被行使，從而發行了相同數量的新股份。此舉使得公司的已發行股份總數達到627,716,432股。此外，公司還披露了其餘未行使的購股權數量，包括購股權激勵計劃和首次公開發售後購股權計劃下授出的購股權，總計70,162,072份。公司提醒股東及潛在投資者，關於私有化的建議、計劃及購股權要約的實行仍需滿足特定條件或獲得豁免，並建議在買賣公司證券時應謹慎行事。董事會對公告內容的準確性承擔責任，並確認經過合理查詢後，公告中的資料無遺漏且無誤導性陳述。
SESONG PHARMACEUTICAL HOLDINGS LIMITED ANNOUNCED ON 3 APRIL 2024 THAT 27,740 SHARE OPTIONS GRANTED UNDER ITS INITIAL PUBLIC OFFERING POST-SALE SHARE OPTION SCHEME HAVE BEEN EXERCISED, THEREBY ISSUING THE SAME NUMBER OF NEW SHARES. This brings the total number of issued shares of the company to 627,716,432 shares. IN ADDITION, THE COMPANY DISCLOSED THE REMAINING OUTSTANDING NUMBER OF SHARE OPTIONS, INCLUDING THOSE GRANTED UNDER THE SHARE OPTION INCENTIVE PROGRAM AND THE INITIAL PUBLIC OFFERING POST-SALE OPTION SCHEME, TOTALING 70,162,072 SHARES. The Company reminds shareholders and potential investors that certain conditions or exemptions are still subject to the implementation of privatization proposals, plans and share purchase agreements, and recommends that caution should be exercised when buying and selling the Company's securities. The Board is responsible for the accuracy of the contents of the announcement and verifies that, after reasonable enquiries, the information in the announcement is free from omissions and is free from misleading statements.
SESONG PHARMACEUTICAL HOLDINGS LIMITED ANNOUNCED ON 3 APRIL 2024 THAT 27,740 SHARE OPTIONS GRANTED UNDER ITS INITIAL PUBLIC OFFERING POST-SALE SHARE OPTION SCHEME HAVE BEEN EXERCISED, THEREBY ISSUING THE SAME NUMBER OF NEW SHARES. This brings the total number of issued shares of the company to 627,716,432 shares. IN ADDITION, THE COMPANY DISCLOSED THE REMAINING OUTSTANDING NUMBER OF SHARE OPTIONS, INCLUDING THOSE GRANTED UNDER THE SHARE OPTION INCENTIVE PROGRAM AND THE INITIAL PUBLIC OFFERING POST-SALE OPTION SCHEME, TOTALING 70,162,072 SHARES. The Company reminds shareholders and potential investors that certain conditions or exemptions are still subject to the implementation of privatization proposals, plans and share purchase agreements, and recommends that caution should be exercised when buying and selling the Company's securities. The Board is responsible for the accuracy of the contents of the announcement and verifies that, after reasonable enquiries, the information in the announcement is free from omissions and is free from misleading statements.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more